Eastgate (ESAQ) 0.1650 $ESAQ
?EastGate Acquisitions Augments Its Sub-Micron Self-Nanoemulsifying Platform Technology
PR Newswire - Mon Aug 18, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it is augmenting its self-emulsifying sub-micron platform technology to include a broad spectrum of delivery options. The various technologies are applicable to the company's current pharmaceutical products in development and can also be employed as effective platforms for delivery of other biologically active compounds. The company recently expanded its new product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome.
EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology
PR Newswire - Tue Jul 29, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces expansion of its pharmaceutical development implementing its sub-micron platform technology. The company's new development direction includes large molecule drugs that will address indications in diabetes and the overall metabolic syndrome.
EastGate Acquisitions Receives Research Grant From Ontario Brain Institute
PR Newswire - Wed Jun 25, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces today that it has received a research grant from the Ontario Brain Institute for its Lorazepam Spray development.
EastGate Acquisitions Enters Into Working Collaboration With Leading Neurologist At Toronto Western Hospital
PR Newswire - Tue Jun 17, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules expands on its pharmaceutical research and development plans.
EastGate Acquisitions Announces Completion Of Private Equity Investment Financing
PR Newswire - Mon Mar 10, 10:00AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, announced today that that it has completed a financing of $1.1 million from the sale of units to selected investors at a price of $0.25 per unit. Each unit consists of one share of restricted common stock and .75 five year warrants with an exercise price of $0.25. The offering closed today. The net proceeds of the financing will be used for working capital, clinical development as well as general corporate and strategic purposes.
EastGate Acquisitions Announces Listing On NASDAQ OTCBB (ESAQ).
PR Newswire - Tue Feb 18, 9:00AM CST
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules., today announced that its common stock has been approved for quotation on the OTC Bulletin Board (OTCBB). The Stock will trade under the ticker symbol "ESAQ".
?EastGate Acquisitions Augments Its Sub-Micron Self-Nanoemulsifying Platform Technology
PR Newswire - Mon Aug 18, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it is augmenting its self-emulsifying sub-micron platform technology to include a broad spectrum of delivery options. The various technologies are applicable to the company's current pharmaceutical products in development and can also be employed as effective platforms for delivery of other biologically active compounds. The company recently expanded its new product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome.
EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology
PR Newswire - Tue Jul 29, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces expansion of its pharmaceutical development implementing its sub-micron platform technology. The company's new development direction includes large molecule drugs that will address indications in diabetes and the overall metabolic syndrome.
EastGate Acquisitions Receives Research Grant From Ontario Brain Institute
PR Newswire - Wed Jun 25, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces today that it has received a research grant from the Ontario Brain Institute for its Lorazepam Spray development.
EastGate Acquisitions Enters Into Working Collaboration With Leading Neurologist At Toronto Western Hospital
PR Newswire - Tue Jun 17, 8:30AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules expands on its pharmaceutical research and development plans.
EastGate Acquisitions Announces Completion Of Private Equity Investment Financing
PR Newswire - Mon Mar 10, 10:00AM CDT
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, announced today that that it has completed a financing of $1.1 million from the sale of units to selected investors at a price of $0.25 per unit. Each unit consists of one share of restricted common stock and .75 five year warrants with an exercise price of $0.25. The offering closed today. The net proceeds of the financing will be used for working capital, clinical development as well as general corporate and strategic purposes.
EastGate Acquisitions Announces Listing On NASDAQ OTCBB (ESAQ).
PR Newswire - Tue Feb 18, 9:00AM CST
EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules., today announced that its common stock has been approved for quotation on the OTC Bulletin Board (OTCBB). The Stock will trade under the ticker symbol "ESAQ".
